Claritas Pharmaceuticals (TSXV:CLAS.H) - Aandelenkoers, Nieuws & Analyse

CLAS.H Overzicht aandelen

A clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.

Over het bedrijf

CLAS.H fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Hoog niveau van niet-contante inkomsten

De laatste financiële rapporten zijn meer dan een jaar oud

Heeft geen betekenisvolle marktkapitalisatie ( CA$945K )

Aandelen zijn zeer illiquide

Claritas Pharmaceuticals, Inc. Concurrenten

Lophos Holdings

CNSX:MESC

CA$858.6k

RAMM Pharma

CNSX:RAMM

CA$1.2m

SugarBud Craft Growers

TSXV:SUGR.H

CA$718.6k

Hempsana Holdings

CNSX:HMPS

CA$591.3k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Claritas Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.025
52 Week Hoogtepunt	CA$0.025
52 Week Laag	CA$0.025
Bèta	0
11 maand verandering	n/a
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-94.68%
5 jaar verandering	-96.88%
Verandering sinds IPO	-99.86%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CLAS.H	CA Pharmaceuticals	CA Markt
7D	0%	7.3%	-0.9%
1Y	n/a	40.8%	27.4%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe CLAS.H presteerde ten opzichte van de Canadian Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe CLAS.H presteerde ten opzichte van de Canadian markt.

Prijsvolatiliteit

Is CLAS.H's price volatile compared to industry and market?
CLAS.H volatility
CLAS.H Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.1%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	3.0%

Stabiele aandelenkoers: CLAS.H heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van CLAS.H in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	n/a	Bob Farrell	claritaspharma.com

Claritas Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Claritas Pharmaceuticals zich tot de beurswaarde?
CLAS.H fundamentele statistieken
Marktkapitalisatie	CA$944.66k
Inkomsten(TTM)	CA$2.50m
Inkomsten(TTM)	n/a

0.0x

Koers/Winstverhouding

0.0x

P/S-verhouding

Is CLAS.H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CLAS.H resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	-US$1.80m
Inkomsten	US$1.81m

Laatst gerapporteerde inkomsten

Sep 30, 2021

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0.0%

Hoe presteerde CLAS.H op de lange termijn?

Bekijk historische prestaties en vergelijking

CLAS.H Overzicht aandelen

Beloningen

Risicoanalyse

Claritas Pharmaceuticals, Inc. Concurrenten

CNSX:MESC

CA$858.6k

CNSX:RAMM

CA$1.2m

TSXV:SUGR.H

CA$718.6k

CNSX:HMPS

CA$591.3k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Insufficient new directors

Claritas Pharmaceuticals, Inc. Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Pharmaceuticals, Inc. Announces Receipt of Comments from Australian Ethics Committee Regarding its Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas Pharmaceuticals, Inc. to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Announces Publication of Peer-Reviewed Article Reporting That R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Recent updates

Insufficient new directors

Claritas Pharmaceuticals, Inc. Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

Claritas Pharmaceuticals, Inc. Announces Receipt of Comments from Australian Ethics Committee Regarding its Phase 1 Clinical Study of R-107 and Closing of Financing

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Claritas Pharmaceuticals, Inc. to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

Claritas Announces Publication of Peer-Reviewed Article Reporting That R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis

Claritas Pharmaceuticals, Inc. announced that it expects to receive funding from Obsidian Global Partners, LLC

Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.18375 million in funding

Claritas Pharmaceuticals, Inc. announced that it expects to receive CAD 0.25 million in funding

Claritas Pharmaceuticals, Inc. Announces Board Changes

Independent Interim Chairman Ronald Erickson has left the company

Independent Director has left the company

Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies

Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107

Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors

Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed

Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Claritas Pharmaceuticals to Focus on Development of R-107 as A Therapy for Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Claritas Pharmaceuticals, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet